1. Home
  2. FRES vs CYCN Comparison

FRES vs CYCN Comparison

Compare FRES & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FRES
  • CYCN
  • Stock Information
  • Founded
  • FRES 2010
  • CYCN N/A
  • Country
  • FRES British Virgin Islands
  • CYCN United States
  • Employees
  • FRES N/A
  • CYCN N/A
  • Industry
  • FRES Medical Specialities
  • CYCN Biotechnology: Pharmaceutical Preparations
  • Sector
  • FRES Health Care
  • CYCN Health Care
  • Exchange
  • FRES Nasdaq
  • CYCN Nasdaq
  • Market Cap
  • FRES 70.9M
  • CYCN 7.8M
  • IPO Year
  • FRES 2020
  • CYCN N/A
  • Fundamental
  • Price
  • FRES $2.96
  • CYCN $3.32
  • Analyst Decision
  • FRES
  • CYCN
  • Analyst Count
  • FRES 0
  • CYCN 0
  • Target Price
  • FRES N/A
  • CYCN N/A
  • AVG Volume (30 Days)
  • FRES 9.9K
  • CYCN 10.4K
  • Earning Date
  • FRES 07-23-2024
  • CYCN 07-26-2024
  • Dividend Yield
  • FRES N/A
  • CYCN N/A
  • EPS Growth
  • FRES N/A
  • CYCN N/A
  • EPS
  • FRES N/A
  • CYCN N/A
  • Revenue
  • FRES $2,345,304.00
  • CYCN N/A
  • Revenue This Year
  • FRES N/A
  • CYCN N/A
  • Revenue Next Year
  • FRES N/A
  • CYCN N/A
  • P/E Ratio
  • FRES N/A
  • CYCN N/A
  • Revenue Growth
  • FRES N/A
  • CYCN N/A
  • 52 Week Low
  • FRES $2.50
  • CYCN $1.75
  • 52 Week High
  • FRES $41.80
  • CYCN $5.25
  • Technical
  • Relative Strength Index (RSI)
  • FRES 40.27
  • CYCN 60.13
  • Support Level
  • FRES $2.81
  • CYCN $2.24
  • Resistance Level
  • FRES $3.70
  • CYCN $3.94
  • Average True Range (ATR)
  • FRES 0.40
  • CYCN 0.43
  • MACD
  • FRES 0.00
  • CYCN 0.14
  • Stochastic Oscillator
  • FRES 35.94
  • CYCN 67.37

About FRES Fresh2 Group Limited

Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.

About CYCN Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Share on Social Networks: